Ipamorelin research: a selective GH pulse, a thin human file, and a regulatory line read straight.

Before the details

Ipamorelin research is unusually clean to summarize, because the most important finding is also the first one. In 1998, scientists showed that this five-amino-acid peptide could make the pituitary release growth hormone without also raising the stress hormone cortisol — the property that gives it its name, selective. Everything since has been about how that pulse behaves, what it does in animals, and whether it does anything useful in people.

The short version of the human side: not much, yet. One pharmacology study mapped how fast ipamorelin clears the body, and one Phase 2 trial tested it after bowel surgery and came up short. There are no large human outcome trials. Below, each section leads with what was measured and the species it was measured in, then names the study. Terms like GHS-R1a (the ghrelin receptor) and IGF-1 (a growth signal the liver makes) are glossed the first time they appear.

The selectivity that defines it

Ipamorelin activates GHS-R1a — the growth hormone secretagogue receptor type 1a, better known as the ghrelin receptor — on the pituitary's GH-producing cells, triggering a calcium-driven pulse of GH release ^[1]. The landmark result is the selectivity: in rat pituitary cells, anaesthetised rats, and conscious swine, ipamorelin released GH as potently as GHRP-6 (swine ED50 2.3 nmol/kg) but did not raise ACTH or cortisol above baseline even at more than 200 times its GH-releasing dose ^[1].

That matters because the older peptides in its family — GHRP-6 and GHRP-2 — raise cortisol and prolactin alongside GH. Ipamorelin's design (an Aib residue at position 1 and D-amino acids that resist enzyme breakdown) produced the first GH secretagogue clean enough to be called selective ^[1]. It is a synthetic ghrelin mimetic: it imitates a hormone the body already makes, at the same receptor.

What is ipamorelin peptide

Ipamorelin peptide is a wholly synthetic pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2, molecular formula C₃₈H₄₉N₉O₅) and a selective agonist of the ghrelin/GHS-R1a receptor ^[1]. It is not an endogenous human peptide — it is a lab-made stand-in for ghrelin that triggers a growth-hormone pulse. Its defining trait is selectivity: GH release without the cortisol and prolactin spillover of earlier growth-hormone-releasing peptides ^[1]. It is classed as a research peptide and is not approved as a drug.

The preclinical record: bone, GI, and body composition

Across animal studies the GH pulse produces measurable downstream effects. In adult female rats, subcutaneous ipamorelin at 18, 90, and 450 µg/day (divided three times daily for 15 days) raised the longitudinal bone growth rate from 42 µm/day in vehicle to 44, 50, and 52 µm/day respectively — dose-dependently — with no measurable change in total IGF-1 ^[4]. That last detail is telling: part of the skeletal effect appears local and GH-pulse-driven rather than dependent on a rise in circulating IGF-1.

In the gut, ipamorelin's ghrelin-receptor activity makes it prokinetic (motility-promoting), which is why it was tested for postoperative ileus. And in mice, twice-daily ipamorelin for two weeks raised fat-pad weight and leptin in both GH-deficient and GH-intact animals — evidence that some of its effect on body composition is GH-independent and runs straight through GHS-R signaling ^[14]. The most recent in-vivo study, a 2024 ferret experiment, found that intraperitoneal ipamorelin (1–3 mg/kg) cut cisplatin-induced body-weight loss by about 24% in the delayed phase, though it had no anti-emetic effect ^[5].

The human evidence, and the trial that fell short

Human data is the part to read carefully. A population PK/PD study in healthy male volunteers (n=8 per dose; five 15-minute IV infusions of 4.21–140.45 nmol/kg) found dose-proportional kinetics, a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg, and a single GH pulse peaking near 40 minutes after dosing ^[2]. That is the cleanest human characterization that exists.

The only published Phase 2 efficacy trial enrolled 114 adults undergoing bowel resection, dosed at 0.03 mg/kg IV twice daily for up to 7 days, and missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo (p=0.15) ^[3]. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of placebo — no ipamorelin-specific safety signal in that short window, but no efficacy either ^[3]. No Phase 3 trial followed. Three 2026 narrative reviews in sports-medicine journals reach the same conclusion: ipamorelin is an investigational GH-axis peptide with preclinical signals but no reproducible human efficacy evidence, and real potential for harm in uncontrolled use ^[16][17][18].

Does cjc-1295 ipamorelin work

The honest answer: the cjc-1295 ipamorelin combination has never been tested as a combination in a controlled human trial for any outcome, so "does it work" cannot be answered from combination data ^[3]. What exists is single-agent pharmacology. CJC-1295, the long-acting GHRH analog, produced dose-dependent 2- to 10-fold GH increases for 6+ days and sustained IGF-1 elevation after a single subcutaneous dose in healthy adults ^[10]. Ipamorelin produces a discrete GH pulse ^[2]. The pairing rests on that separate pharmacology, not on outcome trials of the two together.

What is cjc 1295 ipamorelin

"Cjc 1295 ipamorelin" refers to a popular two-peptide pairing, not a single drug: CJC-1295 is a long-acting GHRH (growth-hormone-releasing hormone) analog, and ipamorelin is a GHRP (growth-hormone-releasing peptide) acting on the ghrelin receptor ^[1][10]. They stimulate GH through two different receptors, which is the rationale for combining a steady GHRH signal with a pulsatile GHRP. The combination itself has no controlled human trial; its logic comes from each agent's separate pharmacology ^[10].

Ipamorelin cjc-1295

The ipamorelin cjc-1295 rationale is mechanistic complementarity: ipamorelin pulses GH via the ghrelin receptor while CJC-1295 raises the GHRH-pathway baseline, and class-level work shows GHRH + GHRP pairs can drive GH release beyond either alone ^[10][11]. Bowers' 30-day study of a GHRP-2/GHRH combination sustained elevated GH and IGF-1 without tachyphylaxis ^[10], and a hexarelin + GHRH study demonstrated true synergism exceeding the additive response ^[11]. None of these used ipamorelin specifically — they establish the class principle the popular stack borrows.

Ipamorelin vs sermorelin

Ipamorelin vs sermorelin is a comparison across two peptide families. Ipamorelin is a GHRP — it acts on the ghrelin/GHS-R1a receptor to pulse GH ^[1]. Sermorelin is a GHRH analog, mimicking growth-hormone-releasing hormone at a different receptor to restore GH secretion ^[8]. A clinical review frames sermorelin's GHRH-analog approach to adult-onset GH insufficiency ^[8]; ipamorelin reaches the same hormone through the ghrelin side of the system. The practical distinction: different receptor, different pathway, and (in community protocols) the two classes are often combined rather than chosen between.

Ipamorelin vs tesamorelin

Ipamorelin vs tesamorelin contrasts a research-grade GHRP with an actually-approved GHRH analog. Tesamorelin is a stabilized GHRH analog; ipamorelin is a ghrelin-receptor GHRP ^[1]. The regulatory gap is the headline difference — ipamorelin has never been approved for any indication ^[3][7], whereas tesamorelin carries an approved indication in its labeled population. Mechanistically they sit on opposite sides of the GH axis (GHRH receptor versus ghrelin receptor), which is again why the two classes are paired in practice rather than treated as substitutes.